Status:
COMPLETED
Clinical Relationship Between Vitamin D-mediated Th17 and Treg Cells and Parkinson's Disease
Lead Sponsor:
Suzhou Municipal Hospital of Anhui Province
Conditions:
Neurology
Immunology
Eligibility:
All Genders
45-80 years
Phase:
EARLY_PHASE1
Brief Summary
The aim of this study is to detect the expression levels of vitamin D, Treg, and Th17 in the peripheral blood of patients with Parkinson\'s disease (PD), investigate the impact of Treg/Th17 im...
Detailed Description
FromJanuary 2023 to July 2024, 50 PD patients and 50 health control groups were collected. All subjects were from the Parkinson\'s outpatient clinic and ward of the Department of Neurology, Suzhou...
Eligibility Criteria
Inclusion
- Meets the age requirement and is in good health.
Exclusion
- Have related vitamin D metabolic diseases (kidney failure, severe liver damage, hereditary 1α hydroxylase deficiency, etc.).
- Have an immune system disorder.
- Have a history of disabling cerebrovascular disease.
- Have a grade 1 or 2 relative with PD.
- Have severe dementia, depression, or serious mental illness.
- Failure to sign the informed consent form.
Key Trial Info
Start Date :
January 1 2023
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
July 1 2024
Estimated Enrollment :
30 Patients enrolled
Trial Details
Trial ID
NCT06539260
Start Date
January 1 2023
End Date
July 1 2024
Last Update
August 26 2024
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Suzhou Hospital of Anhui Medical University
Suzhou, Anhui, China, 234000